World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 25 March 2024
Main ID:  NCT03518086
Date of registration: 04/05/2018
Prospective Registration: Yes
Primary sponsor: Eli Lilly and Company
Public title: An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Scientific title: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Date of first enrolment: June 18, 2018
Target sample size: 1281
Recruitment status: Active, not recruiting
URL:  https://clinicaltrials.gov/ct2/show/NCT03518086
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).  
Phase:  Phase 3
Countries of recruitment
Argentina Australia Austria Belgium Brazil Canada China Croatia
Czechia Denmark France Germany Hungary India Ireland Israel
Italy Japan Korea, Republic of Latvia Lithuania Malaysia Mexico Netherlands
Poland Romania Russian Federation Saudi Arabia Serbia Slovakia Spain Switzerland
Taiwan Turkey Ukraine United Kingdom United States
Contacts
Name:     Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Address: 
Telephone:
Email:
Affiliation:  Eli Lilly and Company
Key inclusion & exclusion criteria

Inclusion Criteria:

- Diagnosis of UC for at least 3 months prior to baseline.

- Confirmed diagnosis of moderately or severely active UC, as assessed by the modified
Mayo score (MMS).

- Demonstrated an inadequate response to, a loss of response to, or an intolerance to
conventional or to biologic therapy for UC.

- If female, must meet the contraception requirements.

Exclusion Criteria:

- Participants with a current diagnosis of Crohn's disease or inflammatory bowel
disease-unclassified (indeterminate colitis).

- Participants with a previous colectomy.

- Participants with current evidence of toxic megacolon.

- Prior exposure to anti-IL12p40 antibodies (e.g. ustekinumab) or anti-IL-23p19
antibodies (e.g. risankizumab, brazikumab, guselkumab or tildrakizumab).



Age minimum: 18 Years
Age maximum: 80 Years
Gender: All
Health Condition(s) or Problem(s) studied
Ulcerative Colitis
Intervention(s)
Drug: Placebo
Drug: Mirikizumab
Primary Outcome(s)
Percentage of Participants With Clinical Remission at Week 12 [Time Frame: Week 12]
Secondary Outcome(s)
Change From Baseline to Week 12 in Bowel Urgency Based on the Urgency Numeric Rating Scale (NRS) [Time Frame: Baseline, Week 12]
Change From Baseline to Week 12 in Health Related Quality of Life: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score [Time Frame: Baseline, Week 12]
Percentage of Participants With Endoscopic Response at Week 12 [Time Frame: Week 12]
Pharmacokinetics (PK): Clearance of Mirikizumab [Time Frame: Predose on week 0, week 4, week 8 and post dose on week 0, 4 and 12]
Percentage of Participants With Endoscopic Remission at Week 12 [Time Frame: Week 12]
Percentage of Participants With Clinical Response at Week 12 [Time Frame: Week 12]
Percentage of Participants With Histologic Remission at Week 12 [Time Frame: Week 12]
Percentage of Participants With Symptomatic Response at Week 12 [Time Frame: Week 12]
Change From Baseline to Week 12 in Fecal Calprotectin [Time Frame: Baseline, Week 12]
Percentage of Participants With Symptomatic Remission at Week 12 [Time Frame: Week 12]
Secondary ID(s)
2017-003229-14
16591
I6T-MC-AMAN
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available: Yes
Date Posted: 28/02/2022
Date Completed:
URL: https://clinicaltrials.gov/ct2/show/results/NCT03518086
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history